A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis

被引:16
作者
Goet, Jorn C. [1 ]
Perez, Carla F. Murillo [1 ,2 ]
Harms, Maren H. [1 ]
Floreani, Annarosa [3 ]
Cazzagon, Nora [3 ]
Bruns, Tony [4 ,5 ]
Prechter, Florian [4 ]
Dalekos, George N. [6 ,7 ]
Verhelst, Xavier [8 ]
Gatselis, Nikolaos K. [6 ,7 ]
Lindor, Keith D. [9 ]
Lammers, Willem J. [1 ]
Gulamhusein, Aliya [2 ]
Reig, Anna [10 ]
Carbone, Marco [11 ,12 ]
Nevens, Frederik [13 ]
Hirschfield, Gideon M. [2 ]
van der Meer, Adriaan J. [1 ]
van Buuren, Henk R. [1 ]
Hansen, Bettina E. [2 ,14 ]
Pares, Albert [10 ]
机构
[1] Erasmus MC, Gastroenterol & Hepatol, Rotterdam, Netherlands
[2] Univ Hlth Network, Toronto Gen Hosp, Toronto Ctr Liver Dis, Toronto, ON, Canada
[3] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
[4] Friedrich Schiller Univ, Jena Univ Hosp, Dept Internal Med 4, Jena, Germany
[5] Univ Hosp RWTH Aachen, Dept Internal Med 3, Aachen, Germany
[6] Gen Univ Hosp Larissa, Natl Expertise Ctr Greece Autoimmune Liver Dis, Dept Med, Larisa, Greece
[7] Gen Univ Hosp Larissa, Natl Expertise Ctr Greece Autoimmune Liver Dis, Res Lab Internal Med, Larisa, Greece
[8] Ghent Univ Hosp, Dept Gastroenterol & Hepatol, Ghent, Belgium
[9] Arizona State Univ, Phoenix, AZ USA
[10] Univ Barcelona, Hosp Clin, Liver Unit, IDIBAPS,CIBERehd, Barcelona, Spain
[11] Univ Milano Bicocca, San Gerardo Hosp, Div Gastroenterol, Dept Med & Surg, Monza, Italy
[12] Univ Milano Bicocca, San Gerardo Hosp, Ctr Autoimmune Liver Dis, Dept Med & Surg, Monza, Italy
[13] Univ Hosp Leuven, Dept Hepatol, KU Leuven, Leuven, Belgium
[14] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
关键词
ACID-TREATED PATIENTS; SERUM BILIRUBIN; TERM SURVIVAL; END-POINTS; FOLLOW-UP; CIRRHOSIS; MODEL; PREDICTION; OUTCOMES; COHORT;
D O I
10.14309/ajg.0000000000001285
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
INTRODUCTION: Comparative data on scores that predict outcome in primary biliary cholangitis (PBC) are scarce. We aimed to assess and compare the prognostic value of the Mayo Risk Score (MRS, 1989 and 1994), UK-PBC score, and GLOBE score in a large international cohort of patients with PBC. METHODS: Ursodeoxycholic acid-treated patients from 7 centers participating in the GLOBAL PBC Study Group were included. The discriminatory performance of the scores was assessed with concordance statistics at yearly intervals up to 5 years. Model for End-stage Liver Disease was included for comparison. Prediction accuracy was assessed by comparing predicted survival and actual survival in Kaplan-Meier analyses. RESULTS: A total of 1,100 ursodeoxycholic acid-treated patients with PBC were included, with a mean (SD) age of 53.6 (12.0) years, of whom 1,003 (91%) were female. During a median follow-up of 7.6 (interquartile range 4.1-11.7) years, 42 patients underwent liver transplantation, and 127 patients died. At 1 year, the concordance statistic for Model for End-stage Liver Disease was 0.68 (95% confidence interval [CI] 0.64-0.72), 0.74 (95% CI 0.67-0.80) for the UK-PBC score, 0.76 (95% CI 0.72-0.81) for the MRS (1989 and 1994), and 0.80 (95% CI 0.76-0.84) for the GLOBE score. The GLOBE score showed superior discriminatory performance, but differences were not statistically different. For all scores, discriminatory performance increased in those with bilirubin >0.6 x ULN and advanced fibrosis estimated with Fibrosis-4. The predicted (median) minus observed 5-year transplant-free survival was +0.4% and +2.5% for the MRS (1989) and GLOBE score, respectively. DISCUSSION: All prognostic scores developed for PBC (GLOBE, UK-PBC, and MRS) demonstrated comparable discriminating performance for liver transplantation or death as well as good prediction accuracy.
引用
收藏
页码:1514 / 1522
页数:9
相关论文
共 33 条
[1]   Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid [J].
Angulo, P ;
Lindor, KD ;
Therneau, TM ;
Jorgensen, RA ;
Malinchoc, M ;
Kamath, PS ;
Dickson, ER .
LIVER, 1999, 19 (02) :115-121
[2]   Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis [J].
Bonnand, AM ;
Heathcote, EJ ;
Lindor, KD ;
Poupon, RE .
HEPATOLOGY, 1999, 29 (01) :39-43
[3]   The UK-PBC Risk Scores: Derivation and Validation of a Scoring System for Long-Term Prediction of End-Stage Liver Disease in Primary Biliary Cholangitis [J].
Carbone, Marco ;
Sharp, Stephen J. ;
Flack, Steve ;
Paximadas, Dimitrios ;
Spiess, Kelly ;
Adgey, Carolyn ;
Griffiths, Laura ;
Lim, Reyna ;
Trembling, Paul ;
Williamson, Kate ;
Wareham, Nick J. ;
Aldersley, Mark ;
Bathgate, Andrew ;
Burroughs, Andrew K. ;
Heneghan, Michael A. ;
Neuberger, James M. ;
Thorburn, Douglas ;
Hirschfield, Gideon M. ;
Cordell, Heather J. ;
Alexander, Graeme J. ;
Jones, David E. J. ;
Sandford, Richard N. ;
Mells, George F. .
HEPATOLOGY, 2016, 63 (03) :930-950
[4]   PROGNOSIS IN PRIMARY BILIARY-CIRRHOSIS - MODEL FOR DECISION-MAKING [J].
DICKSON, ER ;
GRAMBSCH, PM ;
FLEMING, TR ;
FISHER, LD ;
LANGWORTHY, A .
HEPATOLOGY, 1989, 10 (01) :1-7
[5]   A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre [J].
Floreani, Annarosa ;
Caroli, Diego ;
Variola, Angela ;
Rizzotto, Erik Rosa ;
Antoniazzi, Sara ;
Chiaramonte, Maria ;
Cazzagon, Nora ;
Brombin, Chiara ;
Salmaso, Luigi ;
Baldo, Vincenzo .
LIVER INTERNATIONAL, 2011, 31 (03) :361-368
[6]   The new liver allocation system: Moving toward evidence-based transplantation policy [J].
Freeman, RB ;
Wiesner, RH ;
Harper, A ;
McDiarmid, SV ;
Lake, J ;
Edwards, E ;
Merion, R ;
Wolfe, R ;
Turcotte, J ;
Teperman, L .
LIVER TRANSPLANTATION, 2002, 8 (09) :851-858
[7]   BEHAVIORAL PATTERNS OF TOTAL SERUM BILIRUBIN PRIOR TO MAJOR CLINICAL ENDPOINTS IN 3529 PATIENTS WITH PRIMARY BILIARY CHOLANGITIS [J].
Harms, M. H. ;
Pares, A. ;
Mason, A. L. ;
Lammers, W. J. ;
Battezzati, P. M. ;
Floreani, A. ;
LaRusso, N. F. ;
Lindor, K. ;
Nevens, F. ;
Thorburn, D. ;
Kowdley, K. V. ;
Ponsioen, C. ;
Corpechot, C. ;
Hirschfield, G. M. ;
Mayo, M. J. ;
Janssen, H. L. ;
van Buuren, H. R. ;
Invernizzi, P. ;
Hansen, B. E. .
JOURNAL OF HEPATOLOGY, 2016, 64 :S633-S634
[8]   Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome [J].
Harms, Maren H. ;
Lammers, Willem J. ;
Thorburn, Douglas ;
Corpechot, Christophe ;
Invernizzi, Pietro ;
Janssen, Harry L. A. ;
Battezzati, Pier M. ;
Nevens, Frederik ;
Lindor, Keith D. ;
Floreani, Annarosa ;
Ponsioen, Cyriel Y. ;
Mayo, Marlyn J. ;
Dalekos, George N. ;
Bruns, Tony ;
Pares, Albert ;
Mason, Andrew L. ;
Verhelst, Xavier ;
Kowdley, Kris V. ;
Goet, Jorn C. ;
Hirschfield, Gideon M. ;
Hansen, Bettina E. ;
van Buuren, Henk R. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 (02) :254-264
[9]   EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis [J].
Hirschfield, Gideon M. ;
Beuers, Ulrich ;
Corpechot, Christophe ;
Invernizzi, Pietro ;
Jones, David ;
Marzioni, Marco .
JOURNAL OF HEPATOLOGY, 2017, 67 (01) :145-172
[10]   A model to predict survival in patients with end-stage liver disease [J].
Kamath, PS ;
Wiesner, RH ;
Malinchoc, M ;
Kremers, W ;
Therneau, TM ;
Kosberg, CL ;
D'Amico, G ;
Dickson, ER ;
Kim, WR .
HEPATOLOGY, 2001, 33 (02) :464-470